Warner Chilcott and Roche Sue Teva Over Actonel

Following attempts by Teva to obtain regulatory approval of a generic form of Actonel (risedronate), used to treat or prevent osteoporosis and to treat Paget’s bone disease, Warner Chilcott Co. LLC and Hoffmann-La Roche Inc. have launched a suit alleging Teva Pharmaceuticals USA Inc. has infringed one of their patents.

This entry was posted on Thursday, January 27th, 2011 at 10:48 am and is filed under drugs, Intellectual Property, Patents, pharmaceuticals, Teva. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

One Response to Warner Chilcott and Roche Sue Teva Over Actonel

  1. Pharma & Biotech Global Week in Review 2 February 2011 from IP Think Tank says:
    February 2, 2011 at 11:54 am

    [...] Actonel (risedronate) – US: Warner Chilcott and Roche sue Teva over Actonel (The IP Factor) [...]

    Reply

Leave a Reply

Fill in your details below or click an icon to log in:

Gravatar
WordPress.com Logo

You are commenting using your WordPress.com account. ( Log Out / Change )

Twitter picture

You are commenting using your Twitter account. ( Log Out / Change )

Facebook photo

You are commenting using your Facebook account. ( Log Out / Change )

Cancel

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 92 other followers